In a sector note on U.S. Medical Supplies and Devices, UBS initiated coverage of Tandem Diabetes with a Neutral rating and $45 price target.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on TNDM:
- Tandem Diabetes announces NEJM publication of study on t:slim X2 insulin pump
- Tandem pairing with Abbott sensors can be ‘big deal,’ says Lake Street
- 3 Stocks to Buy Today, 2/24/2023, According to Top Analysts
- Tandem Diabetes price target lowered to $74 from $80 at Craig-Hallum
- Tandem Diabetes price target lowered to $50 from $70 at Piper Sandler